PLK1 and neoplasm: Evidence that PLK1 inhibitors (e.g., volasertib) can reduce tumor cell proliferation and migration, induce apoptosis, and sensitize cells to chemotherapy highlights the promise of PLK1 as an anticancer drug target [27, 28].